Search results for "once daily"

showing 5 items of 15 documents

Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma

2021

INTRODUCTION Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved on the market has been tiotropium. AREAS COVERED We reviewed recent clinical studies evaluating the safety and efficacy of LABA/LAMA/ICS fixed dose combinations by searching Pu…

Pulmonary and Respiratory Medicinemedicine.medical_specialtycorticosteroidFixed-dose combinationLABAAsthma corticosteroid fixed dose combination ICS inhaler LABA LAMA once daily combination uncontrolled asthmaMuscarinic Antagonistsonce daily combinationQuinolonesSettore MED/10 - Malattie Dell'Apparato RespiratorioinhalerAdrenal Cortex HormonesInternal medicineAdministration InhalationImmunology and AllergyMedicineHumansfixed dose combinationAdrenergic beta-2 Receptor AgonistsAsthmaFluticasonebiologyInhalationuncontrolled asthmabusiness.industryInhalerPublic Health Environmental and Occupational HealthLAMALamamedicine.diseasebiology.organism_classificationGlycopyrrolateFluticasone-Salmeterol Drug CombinationAsthmarespiratory tract diseasesDrug CombinationsICSIndansIndacaterolSalmeterolbusinessMometasone Furoatehormones hormone substitutes and hormone antagonistsmedicine.drug
researchProduct

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

2012

Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment of COPD. Glycopyrronium is a novel LAMA, currently in development for COPD. Phase II studies have shown that glycopyrronium 50 μg once daily provides clinically significant 24-hour bronchodilation with a rapid onset of action, which is faster than that of tiotropium, and a favorable safety and tolerability profile. The Phase III GLycopyrronium bromide in COPD airWays (GLOW) progr…

Time FactorsCombination therapymuscarinic antagonistReviewMuscarinic AntagonistsPlaceboNVA237Severity of Illness IndexDrug Administration Schedulechronic obstructive pulmonary diseaseglycopyrroniumPulmonary Disease Chronic ObstructiveAdministration InhalationHumansMedicineGlycopyrronium bromideAdverse effectLungCOPDExercise Tolerancebiologybusiness.industryGeneral MedicineLamamedicine.diseasebiology.organism_classificationonce dailyGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeTolerabilityAnesthesiaIndacaterolbusinessmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and inda…

2021

business.industryImmunologyFixed-dose combinationmedicineImmunology and AllergyIndacaterolMometasone furoateOnce dailyPharmacologybusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

The normal circadian pattern of blood pressure: implications for treatment

2004

Blood pressure fluctuates over 24 h following a circadian rhythm that reaches a peak in the morning shortly after awakening. The onset of many acute cardiovascular and cerebrovascular events shows a synchronous cyclical pattern, with the highest incidence of morbidity and mortality in the early morning hours. Strong, although circumstantial, evidence suggests that the early morning surge in blood pressure may contribute to the onset of acute cardiovascular episodes. Sustained blood pressure control that blunts the early morning blood pressure surge may help to reduce the incidence of these events. Antihypertensive agents are needed that provide smooth and sustained blood pressure control fo…

medicine.medical_specialtyAngiotensin receptorbusiness.industryIncidence (epidemiology)medicine.medical_treatmentChronotherapy (sleep phase)General MedicineBlood pressureInternal medicinemedicineCardiologyCircadian rhythmTelmisartanOnce dailybusinessmedicine.drugMorningInternational Journal of Clinical Practice
researchProduct

Efficacy of Once-Daily Tiotropium Respimat ® on Lung Function and Asthma Control in Adults with Asthma at GINA Steps 2–5

2018

medicine.medical_specialtyRespimatbusiness.industryInternal medicineAsthma controlImmunologymedicineImmunology and AllergyOnce dailymedicine.diseasebusinessLung functionAsthmaJournal of Allergy and Clinical Immunology
researchProduct